TrialBlood cancer journal2026

Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26).

Juying Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.